HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Czernin, J. Articles by Schelbert, H. R. Search for Related Content PubMed PubMed Citation Articles by Czernin, J. Articles by Schelbert, H. R.

Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California

Correspondence: For correspondence or reprints contact: Johannes Czernin, MD, Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095-6948. E-mail: jczernin{at}mednet.ucla.edu

PET/CT with ¹⁸F-FDG is increasingly being used for staging, restaging, and treatment monitoring for cancer patients. CT is still frequently used only for attenuation correction and lesion localization. However, increasing sales of high-end scanners that combine PET with 64-detector CT strongly suggest that the field is moving toward a comprehensive concept, whereby diagnostic CT studies during intravenous contrast material application are combined with the highest-quality PET studies. At many institutions, in-line PET/CT has replaced separately acquired PET and CT examinations for many oncologic indications. This replacement has occurred despite the fact that only a relatively small number of well-designed prospective studies have verified imaging findings against the gold standard of histopathologic tissue evaluation. However, a large number of studies have used acceptable reference standards, such as pathology, imaging, and other clinical follow-up findings, for validating PET/CT findings. From these data, we believe, has emerged reliable evidence in support of the notion that PET/CT offers diagnostic advantages over its individual components for the major cancers.

Key Words: cancer • staging • PET/CT

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				T. A. Heusner, S. Kuemmel, L. Umutlu, A. Koeninger, L. S. Freudenberg, E. A.M. Hauth, K. R. Kimmig, M. Forsting, A. Bockisch, and G. Antoch Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography J. Nucl. Med., August 1, 2008; 49(8): 1215 - 1222. [Abstract] [Full Text] [PDF]

				A. K. Buck, S. Nekolla, S. Ziegler, A. Beer, B. J. Krause, K. Herrmann, K. Scheidhauer, H.-J. Wester, E. J. Rummeny, M. Schwaiger, et al. SPECT/CT J. Nucl. Med., August 1, 2008; 49(8): 1305 - 1319. [Abstract] [Full Text] [PDF]

				D. W. Townsend Dual-Modality Imaging: Combining Anatomy and Function J. Nucl. Med., June 1, 2008; 49(6): 938 - 955. [Abstract] [Full Text] [PDF]

				J. P. van Meerbeeck, S. Meersschout, R. De Pauw, I. Madani, and W. De Neve Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects Oncologist, June 1, 2008; 13(6): 700 - 708. [Abstract] [Full Text] [PDF]

				N. Federman and S. A. Feig PET/CT in Evaluating Pediatric Malignancies: A Clinician's Perspective J. Nucl. Med., December 1, 2007; 48(12): 1920 - 1922. [Full Text] [PDF]

				J. Czernin and H. R. Schelbert Introduction J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S. [Full Text] [PDF]